Eugene Zhukovsky,
Chief Scientific Officer
Since January 2015 Dr. Zhukovsky is the Chief Scientific Officer of Biomunex Pharmaceuticals, where he is developing BiXAb® bispecific antibodies for immune-oncology. He has over two decades of professional experience in the field of biotherapeutics research and development. Before joining Biomunex, he served as the CSO of Affimed Therapeutics; there he was responsible for the advancement of candidate therapeutics from discovery to the clinic and novel technology development. Prior to that he was a Senior Research Fellow in the Biotherapeutics Department at Boehringer Ingelheim Pharmaceuticals, Inc. leading antibody discovery efforts. Prior to that Dr. Zhukovsky was an Associate Director at Xencor, Inc. where he led translational research efforts resulting in several clinical candidates for hematological malignancies. Dr. Zhukovsky began his professional career employing phage display technology at Neurex Corporation before moving to Lynx Therapeutics (now Illumina, Inc.) to work on the development of genomics technologies. Dr. Zhukovsky performed a postdoctoral fellowship at Genentech, Inc. He received a PhD in biochemistry from Brandeis University.
|
|
|
